Magenta Therapeutics was co-founded, seeded, and incubated by Atlas in 2015 to revolutionize stem cell transplant as the new treatment paradigm for autoimmune and blood-based diseases. By more effectively preparing patients to receive stem cell transplants and delivering higher quality replacement stem cells, Magenta aims to make curative stem cell therapies available to substantially more patients than are currently receiving these life-saving treatments. Magenta went public in June 2018 (NASDAQ: MGTA).
| Headquarters | Cambridge, MA |
| Website | www.magentatx.com |
| Pipeline | Phase 2 |
| @MagentaTx | |
| Partners | Be The Match, Heidelberg Pharma |